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Background: The EVEREST II randomized trial showed that percutaneous repair of the
mitral valve with the MitraClip® device (Abbott Vascular, Santa Clara, CA) reduced
mitral regurgitation less completely than conventional surgery, but was associated with
superior safety and similar clinical outcomes at 12 months. The potential cost-
effectiveness (CE) of the MitraClip procedure compared with mitral valve surgery is not
presently known.
Methods: We conducted a 12-month U.S. CE analysis comparing the MitraClip
procedure with mitral valve surgery based on the EVEREST II trial. Index admission
costs were calculated using hospital billing data or estimated using regression models.
Costs for follow-up hospitalizations were estimated based on Medicare reimbursement.
Resource-based costs were also included for rehabilitative and long-term care services.
SF-36 data, collected at baseline, 1 and 12 months, was used to calculate quality-adjusted
life years (QALYs). Results were assessed in a primary modified intention to treat (mITT)
population excluding randomized but not treated patients.
Results: Results were sensitive to assumptions on the duration of QOL benefit with
MitraClip relative to surgery (present at 1 but not 12 months), the price of the MitraClip
device, and the analytic population. In our base case the MitraClip strategy slightly
increased QALYs through 12 months (0.015) At the study price of $18,000 the clip
strategy reduced costs by $2,200/patient, making MitraClip economically dominant. At a
clip price of $26,200 (approximate European sales price), overall costs were higher with
the clip strategy by $6,192 and the incremental CE ratio was unfavorable ($400,000 per
QALY gained). In a sensitivity analysis limiting to patients with acute procedural success
(per protocol population), the QALY gain was larger (0.041), the cost-offsets with the clip
greater, and cost-effectiveness more favorable (dominant at a MitraClip price of $18,000,
$54,000 per QALY gained at $26,200).
Conclusions: The potential cost-effectiveness of MitraClip compared with mitral valve
surgery in EVEREST II varied depending primarily on MitraClip price and acute
procedural success.
TCT-787
Effectiveness of Transcatheter Mitral Valve Repair in Degenerative Mitral
Regurgitation in High Surgical Risk Patients
D. Scott Lim1, Saibal Kar2, Patrick Whitlow3, Michael Argenziano4,
Alfredo Trento5, Gorav Ailawadi1, Donald Glower6, Ted Feldman7
1University of Virginia Health System, Charlottesville, VA, 2Cedars-Sinai Medical
Center, Los Angeles, USA, 3Cleveland Clinic, Cleveland, Ohio, 4Columbia
University Medical Center, New York, New York, 5Cedars-Sinai Medical Center,
Los Angeles, California, 6Duke University Medical Center, Durham, North
Carolina, 7Evanston Northshore Healthcare, Evanston, IL
Background: Mitral valve surgery is generally indicated for patients with severe
degenerative mitral regurgitation (DMR). However, surgical correction of MR may not
always be possible in high surgical risk patients. The purpose of this analysis is to describe
clinical benefit including improvements in left ventricular (LV) size and function
observed following treatment with the MitraClip device (Abbott Vascular, Menlo Park,
CA) in high surgical risk patients with DMR.
Methods: EVEREST II High Risk Study and REALISM Continued Access Registry
patients had significant MR (3	/4	) and were deemed high risk for surgery as
determined by a STS predicted surgical mortality 12% or surgeon assessment. Clinical
measures including NYHA Functional Class, quality of life (QOL) and hospitalizations
for CHF as well as echocardiographic measurements analyzed by an independent core lab
were evaluated.
Results: 62 high surgical risk DMR patients underwent a MitraClip procedure with a
94% implant rate. Patients were elderly (mean age 838 yrs) with significant comor-
bidities (CHF 100%, CAD 75%, prior cardiac surgery 47%). The mean predicted surgical
mortality by STS calculator was 14.89.1%. Observed mortality at 30 days and 12
months was 6.5% and 25.8%, respectively. 37 patients had matched echocardiograms
between Baseline and 12 months, of which 78% achieved MR severity 2	. Clinical
benefit was demonstrated at 12 months with significant improvements in LV volumes,
NYHA Functional Class, and QOL (Table). Compared to 12 months prior the MitraClip
procedure, the annual rate of CHF hospitalizations decreased 77% in the 12 months
post-procedure.
MeanSD (N) LVEDV (ml) LVESV (ml)
Baseline 13540 (51) 5126 (51)
30 Days† 12341 (51) 5327 (51)
Change from Baseline to 30 Days -1216 213
p-value 0.0001 0.32
Baseline 13743 (35) 5129 (35)
12 Months 11838 (35) 4925 (35)
Change from Baseline to 12
Months
-1920 -214
p-value 0.0001 0.38
LV Ejection Fraction (%)
NYHA Functional
Class I/II (%)
638 (51) 18 (55)
5810 (51) 73 (55)
-58 55
0.0001 0.0001
649 (35) 21 (39)
5910 (35) 85 (39)
-57 64
0.0004 0.0001
Quality of Life
PCS Score
Quality of Life
MCS Score
3110 (51) 4912 (51)
3810 (51) 5011 (51)
710 112
0.0001 0.59
3310 (34) 4913 (34)
3912 (34) 5310 (34)
69 412
0.0005 0.085
†Echocardiographic measures were evaluated at Discharge
PCS  Physical Component Summary, MCS  Mental Component Summary
Conclusions: The MitraClip procedure resulted in significant improvements in MR
severity, LV reverse remodeling, and clinical outcomes and is an important therapeutic
option for patients with significant degenerative MR who are not suitable candidates for
surgery.
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Background: EVEREST II is a prospective multi-center RCT comparing safety and
effectiveness of the MitraClip System with mitral valve (MV) surgery in the treatment of
severe (3	 or 4	) mitral regurgitation (MR). We report outcomes at 3 years to evaluate
durability of clinical endpoints and changes in MR severity and left ventricular (LV)
volumes.
Methods: 279 patients, randomized 2:1 to transcatheter MitraClip treatment or surgery
were enrolled at 37 sites in North America. Each patient had core lab assessed
echocardiograms prior to enrollment. Clinical benefit was assessed at 3 years by measures
of LV function, NYHA Functional Class (NYHA-FC) and freedom from mortality and
MV surgery or re-operation.
Results: Mean age was 67 years; baseline LV ejection fraction was 60%. Half were in
NYHA-FC III/IV and 73% had degenerative MR. Through 3 years, 24 MitraClip and 11
surgery patients withdrew. Of 258 treated patients, Kaplan-Meier (KM) estimate of
freedom from mortality at 3 years was 87% in MitraClip and 85% in surgery groups. KM
estimate of freedom from surgery was 78% in MitraClip patients and freedom from
re-operation was 94% in surgery patients, both unchanged from 1 year. In patients with
matched data, MR severity was  2	 in 84% of MitraClip and 96% of surgery groups.
Compared to baseline, LV end-diastolic volumes at 3 years decreased by 29 mL and 44
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